Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 35605176

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2022 Aug 25
First author
Seymour JF

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2022 Aug 25;140(8):797-798. doi: 10.1182/blood.2022016927.
    note
    Source null
    related pmid
    36006672
    relationship
    Comment in
  2. citation
    Int J Hematol. 2023 Oct;118(4):526-528. doi: 10.1007/s12185-023-03646-3.
    note
    Source null
    related pmid
    37581752
    relationship
    Comment in

Authors and identifiers

  1. name
    Seymour JF
    type
    Author
  2. name
    Kipps TJ
    type
    Author
  3. name
    Eichhorst BF
    type
    Author
  4. name
    D'Rozario J
    type
    Author
  5. name
    Owen CJ
    type
    Author
  6. name
    Assouline S
    type
    Author
  7. name
    Lamanna N
    type
    Author
  8. name
    Robak T
    type
    Author
  9. name
    de la Serna J
    type
    Author
  10. name
    Jaeger U
    type
    Author
  11. name
    Cartron G
    type
    Author
  12. name
    Montillo M
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Seymour JF
    type
    Author
  2. name
    Kipps TJ
    type
    Author
  3. name
    Eichhorst BF
    type
    Author
  4. name
    D'Rozario J
    type
    Author
  5. name
    Owen CJ
    type
    Author
  6. name
    Assouline S
    type
    Author
  7. name
    Lamanna N
    type
    Author
  8. name
    Robak T
    type
    Author
  9. name
    de la Serna J
    type
    Author
  10. name
    Jaeger U
    type
    Author
  11. name
    Cartron G
    type
    Author
  12. name
    Montillo M
    type
    Author
bibliography ids
  1. nci-bib-365e976be4c48a0a76995afc
book metadata
content sha256
d2157f9b761bece728d0413c0b8d3d7f8062a71898bcfe136556d596a0ba6e4e
document type
citation
dois
  1. 10.1182/blood.2021015014
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:35605176
immutable id
pubmed:35605176@d2157f9b761bece728d0413c0b8d3d7f8062a71898bcfe136556d596a0ba6e4e
journal
abbreviation
Blood
issn electronic
1528-0020
issn print
0006-4971
issue
8
name
Blood
nlm unique id
7603509
pages
839-850
volume
140
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2022 Aug 25;140(8):797-798. doi: 10.1182/blood.2022016927.
    note
    Source null
    related pmid
    36006672
    relationship
    Comment in
  2. citation
    Int J Hematol. 2023 Oct;118(4):526-528. doi: 10.1007/s12185-023-03646-3.
    note
    Source null
    related pmid
    37581752
    relationship
    Comment in
outcomes validated
false
pmid
35605176
provenance
batch id
9d150d55960e0c12aada
provider
NCBI PubMed ESummary
record sha256
0c31685dea51426d639be5227817302e6e4fda19fc7c4460837043ae4e5d9729
response sha256
2d4ef1cc8137eef6e7216f66bf8601c3899bc663b8626f412794d39585de6b6b
retrieved at
2026-09-09T23:48:09.820498+00:00
publication date
display
2022 Aug 25
precision
day
year
2022
publication types
  1. Journal Article
  2. Randomized Controlled Trial
  3. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/35605176/
title
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.

Preserved source evidence · Not medical advice